<DOC>
	<DOCNO>NCT01990118</DOCNO>
	<brief_summary>The purpose study establish therapeutic equivalence Gengraf® standard treatment Neoral® treatment period 6 month stable renal allograft transplant recipient respect drug level , dosage , acute graft rejection adverse event .</brief_summary>
	<brief_title>Gengraf Conversion Study Stable Renal Allograft Transplant Recipients</brief_title>
	<detailed_description>The introduction cyclosporine ( CsA ) clinical practice result improvement acute renal allograft rejection rate graft survival renal transplant patient . Gengraf microemulsion formulation CsA though grant AB-rated equivalent Neoral , concern use generic drug transplantation , undertook study evaluate clinical efficacy safety Gengraf . We conduct multicenter , randomize , open label study establish equivalence Gengraf Neoral stable renal transplant recipient treatment period 6 month . 6 month post transplant patient stable graft function receive stable dose neoral recruit study . Eligible patient randomly assign remain Neoral convert equal milligram-for-milligram dose Gengraf . The primary end-point serum creatinine 26 week .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>1 . Written inform consent obtain patient parents/guardian . 2 . Patients 6 month post transplant 3 . Stable graft function i.e . serum creatinine le 300 umol/l 4 . Patients currently stable dose capsule Neoral within last one month 1 . Multiple organ transplantation 2 . Pregnant nursing woman , woman childbearing potential without effective method birth control . Effective birth control method oral contraception , Norplant , surgical sterilization , Intra Uterine Device diaphragm conjunction spermicidal foam condom male partner . 3 . Participation drug trial patient receive investigational drug within 30 day precede screen phase study . 4 . Those person directly involve conduct study . 5 . Active infection time screen enrollment trial . 6 . Acute graft rejection within past 3 month 7 . Mentally unstable history mental diseases 8 . History drug alcohol abuse within past 2 year . 9 . History noncompliance medical regimen patient unwilling unable comply protocol . 10 . Decompensated liver disease 11 . Any serious medical condition disability , opinion investigator , would interfere treatment assessment preclude completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Renal transplant</keyword>
	<keyword>Renal allograft rejection</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Gengraf</keyword>
</DOC>